Recombinant alpha-2b-interferon treatment in a patient with chronic C concomittant hepatitis and outbreak of ulcerative colitis;Tratamiento con interferon alfa-2b recombinante de una paciente con hepatitis cronica C y brote de colitis ulcerosa concomitante

Revista Espanola de Enfermedades Digestivas

Volumn 89, Issue 5, 1997, Pages 399-401

  De Diego Lorenzo, A ^a   Kashoob, M ^a   Romero, M ^a   Parera, A ^a   Duran F G ^a   Piqueras, B ^a   Santos, L ^a   Cos, E ^a   Clemente, G ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

chronic C hepatitis; interferon; ulcerative colitis autoimmunity

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT;

ADULT; ARTICLE; AUTOIMMUNITY; CASE REPORT; CHRONIC ACTIVE HEPATITIS; DRUG CONTRAINDICATION; FEMALE; HEPATITIS C; HUMAN; SUBCUTANEOUS DRUG ADMINISTRATION; ULCERATIVE COLITIS;

ADULT; ANTIVIRAL AGENTS; COLITIS, ULCERATIVE; FEMALE; HEPATITIS C; HUMANS; INTERFERON ALFA-2B;

EID: 0031136572     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991;325:928-37 y 1008-16.
2. Shanaham F. Pathogenesis of ulcerative colitis. Lancet 1993;342:407-11.
3. Snook J. Are the inflammatory bowel diseases autoimmune disordes? Gut 1990;31:961-3.
4. Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16:273-81.
5. Terrault N, Wright T. Interferon and hepatitis C. N Engl J Med 1995;332:1509-11.
6. Renault PF; Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis 1989;9:273-7.
7. Ronnblom L, Alm G, Oberg K. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991;115:178-83.
8. Lowes JR, Jewell DP. The immunology of inflammatory bowel disease. Springer Sem Immunopathology 1990;12:251-68.
9. Mayer L, Eisenhardt D, Salomon P, et al. Expression of class II molecules on intestinal epithelial cells in humans: differences between normal and inflammatory bowel disease. Gastroenterology 1991;100:3-12.
10. Snook JA, Lowes JR, Wukc. Priddle JD. Serum and tissue autoantibodies to colonic ephitelium in ulcerative colitis. Gut 1991;32:163-6.
11. Tural C, Cuxart A, Miralpeix E. Anticuerpos contra el citoplasma de los neutrófilos (ANCA) y enfermedad inflamatoria intestinal. Gastroenterol Hepatol 1992;15:588-92.
12. Bianchi L, Gudat FG. Histo and immunopathology of viral hepatitis. En: Deinhart F, Heinhardt J. (Eds). Viral Hepatitis: Laboratory and Clinical Science. Marcel Dekker Inc., New York 1983:335-82.
13. Moreno Otero R, García Monzón C, De Castro M, García Buey L. Patogenia de las hepatitis crónicas. En: Rodés J, Chantar C. VII Curso de actualización en Gastroenterología y Hepatología. JR Prous Ed, Barcelona, 1994:1-12.
14. Piqueras B, Pérez Roldán F, De Diego A, et al. Aparición de autoanticuerpos no organoespecíficos tras el tratamiento con interferón en las hepatitis crónicas VHC: signification clínica y valoración de la modificación de la respuesta. (Abstract). Rev Esp Enf Digest 1994;85(Supl 1):70-1.
15. Marcellin O, Pouteau M, Messian O, Bok B, Erlinger S. Virus de l'hépatite C, interféron alpha et dysthyroïdie. Gastroenterol Clin Biol 1993;17:887-9.
16. Mayet WJ, Hess G, Gerken G, Rossol S, Voth R, Manns M, et al. Treatment of chronic type B hepatitis with recombinant alfa-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 1989;10:24-8.
17. Mitoro A, Yoshikawa M, Thomas K, et al. Exacerbacion of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C. Intern Med 1993;32:327-31.
18. Legaz ML, Artaza T, Alcántara M, Sánchez JJ, López I, Martínez Potenciano JL. Tratamiento con interferon alfa-2 recombinante en un paciente con hepatitis crónica por virus B y colitis ulcerosa. Gastroenterol Hepatol 1996;19:55-7.
19. Harrison PV, Peat MJ. Effects of interferon on psoriasis. Lancet 1986:457-8.